Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.80 +1.6%	$36.82	$23.42 ▼ $62.58	$2.25B	0.8	966,978 shs	722,567 shs
DNLI Denali Therapeutics	$15.49 +1.7%	$14.31	$10.57 ▼ $33.33	$2.26B	1.36	1.74 million shs	2.74 million shs
OCUL Ocular Therapeutix	$12.30 +1.4%	$10.91	$5.78 ▼ $12.91	$2.14B	1.49	2.10 million shs	1.41 million shs
RZLT Rezolute	$7.00 +0.6%	$5.42	$2.21 ▼ $7.15	$608.97M	0.18	644,389 shs	1.13 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+1.57%	+4.84%	-4.34%	+30.20%	-17.62%
DNLI Denali Therapeutics	+1.71%	+5.37%	+7.05%	+15.42%	-38.04%
OCUL Ocular Therapeutix	+1.40%	-2.54%	+2.84%	+68.49%	+33.26%
RZLT Rezolute	+0.57%	+7.69%	+19.05%	+79.95%	+60.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3701 of 5 stars	3.4	2.0	4.3	2.9	0.8	1.9
DNLI Denali Therapeutics	4.1969 of 5 stars	3.6	1.0	4.7	3.0	3.3	0.0
OCUL Ocular Therapeutix	4.1001 of 5 stars	3.5	3.0	4.1	2.8	1.7	0.0
RZLT Rezolute	3.1846 of 5 stars	3.6	3.0	0.0	2.4	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	45.19% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	117.01% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	39.84% Upside
RZLT Rezolute	3.17	Buy	$12.20	74.29% Upside

Current Analyst Ratings Breakdown

Latest RZLT, OCUL, AGIO, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.76	N/A	N/A	$23.57 per share	1.65
DNLI Denali Therapeutics	$330.53M	6.85	N/A	N/A	$7.02 per share	2.21
OCUL Ocular Therapeutix	$63.72M	33.59	N/A	N/A	$1.76 per share	6.99
RZLT Rezolute	N/A	N/A	N/A	N/A	$2.19 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.53	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	N/A
RZLT Rezolute	-$68.46M	-$1.15	N/A	N/A	N/A	N/A	-70.09%	-63.08%	9/18/2025 (Estimated)

Latest RZLT, OCUL, AGIO, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/18/2025	Q4 2025	RZLT Rezolute	-$0.22	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
DNLI Denali Therapeutics	0.01	10.27	10.27
OCUL Ocular Therapeutix	0.23	10.10	10.02
RZLT Rezolute	N/A	8.43	8.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DNLI Denali Therapeutics	92.92%
OCUL Ocular Therapeutix	59.21%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
DNLI Denali Therapeutics	12.50%
OCUL Ocular Therapeutix	2.30%
RZLT Rezolute	18.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
OCUL Ocular Therapeutix	230	173.99 million	169.99 million	Optionable
RZLT Rezolute	40	87.00 million	71.00 million	Optionable

RZLT, OCUL, AGIO, and DNLI Headlines

Recent News About These Companies

Rezolute appoints Karnawat as Chief Commercial Officer

August 20 at 8:01 PM | msn.com

Rezolute Appoints New Chief Commercial Officer

August 20 at 8:01 PM | msn.com

Rezolute (NASDAQ:RZLT) Hits New 52-Week High - What's Next?

August 20 at 5:14 PM | marketbeat.com

Rezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer to Advance Commercialization of ersodetug

August 20 at 8:11 AM | quiverquant.comQ

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

August 20 at 7:30 AM | globenewswire.com

Altium Capital Management LLC Has $881,000 Position in Rezolute, Inc. (NASDAQ:RZLT)

August 14, 2025 | marketbeat.com

Vivo Capital LLC Sells 685,272 Shares of Rezolute, Inc. (NASDAQ:RZLT)

August 9, 2025 | marketbeat.com

Rezolute, Inc. (NASDAQ:RZLT) Given Average Recommendation of "Buy" by Brokerages

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Rezolute Cut by Cantor Fitzgerald

July 28, 2025 | marketbeat.com

Rezolute (NASDAQ:RZLT) Trading 6.5% Higher - Here's Why

July 26, 2025 | marketbeat.com

Cantor Fitzgerald Comments on Rezolute FY2026 Earnings

July 26, 2025 | marketbeat.com

Rezolute (NASDAQ:RZLT) Sets New 52-Week High - Here's What Happened

July 25, 2025 | marketbeat.com

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

July 22, 2025 | globenewswire.com

Rezolute Completes Enrollment for Phase 3 sunRIZE Study

July 18, 2025 | tipranks.com

Rezolute files to sell 1.3M shares of common stock for holders

July 18, 2025 | msn.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of ...

July 10, 2025 | finance.yahoo.com

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

July 9, 2025 | globenewswire.com

Brian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 27, 2025 | insidertrades.com

Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 5,000 Shares of Stock

June 25, 2025 | insidertrades.com

Young-Jin Kim Buys 1,230,769 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

June 24, 2025 | insidertrades.com

Rezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%

June 3, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT, OCUL, AGIO, and DNLI Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.80 +0.60 (+1.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$38.81 +0.01 (+0.02%)

As of 08/22/2025 05:51 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.49 +0.26 (+1.71%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.56 +0.07 (+0.48%)

As of 08/22/2025 07:34 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Ocular Therapeutix NASDAQ:OCUL

$12.30 +0.17 (+1.40%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.30 0.00 (0.00%)

As of 08/22/2025 06:36 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Rezolute NASDAQ:RZLT

$7.00 +0.04 (+0.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.15 +0.15 (+2.20%)

As of 08/22/2025 07:56 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time